Kiran Mazumdar support for pharma

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

image
Business Standard
177 22
Business Standard

Kiran Mazumdar support for pharma

BS Reporter  |  Chennai/ Chandigarh 

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

RECOMMENDED FOR YOU

Kiran Mazumdar support for pharma

Kiran Mazumdar-Shaw, CMD, Biocon Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business.

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard